BACKGROUND: In @entity1030 ( @entity1030 ), two major pathological changes that occur are the loss of @entity2383 and airspace enlargement. To treat @entity1030 , it is crucial to repair damaged lung tissue and regenerate the lost alveoli. Type II alveolar epithelial cells (AECII) play a vital role in maintaining lung tissue repair, and amniotic fluid-derived mesenchymal stromal cells (AFMSCs) possess the characteristics of regular mesenchymal stromal cells. However, it remains untested whether transplantation of @entity35 AFMSCs (rAFMSCs) might @entity651 caused by @entity2415 by increasing the expression of @entity18889 and @entity10459 and inhibiting AECII apoptosis. METHODS: We analyzed the phenotypic characteristics, differentiation potential, and karyotype of rAFMSCs, which were isolated from pregnant @entity35 . Moreover, we examined the lung morphology and the expression levels of @entity18889 and @entity10459 in @entity35 with @entity2415 after cigarette-smoke exposure and intratracheal lipopolysaccharide instillation and rAFMSC transplantation. The ability of rAFMSCs to differentiate was measured, and the apoptosis of AECII was evaluated. RESULTS: In rAFMSCs, the surface antigens CD29, @entity3802 , @entity33305 , @entity18715 , CD105, and CD166 were expressed, but @entity45685 , @entity39223 , @entity6098 , and @entity1008 were not detected; rAFMSCs also strongly expressed the mRNA of octamer-binding transcription factor 4, and the cells could be induced to differentiate into adipocytes and osteocytes. Furthermore, rAFMSC treatment up-regulated the levels of @entity18889 , @entity10459 , and thyroid transcription factor 1 and inhibited AECII apoptosis, and rAFMSCs appeared to be capable of differentiating into AECII-like cells. @entity651 caused by @entity2415 was alleviated after rAFMSC treatment. CONCLUSIONS: rAFMSCs might differentiate into AECII-like cells or induce local regeneration of the lung alveolar epithelium in vivo after transplantation and thus could be used in @entity1030 treatment and lung regenerative therapy.

Therapeutic effects of amniotic fluid-derived mesenchymal stromal cells on XXXX in @entity35 with @entity2415 .

@entity33305 :: ('58813(Tax:10116)', 'Gene') :: ['CD73'] @entity6098 :: ('305081(Tax:10116)', 'Gene') :: ['CD34'] @entity1008 :: ('24699(Tax:10116)', 'Gene') :: ['CD45'] @entity39223 :: ('365367(Tax:10116)', 'Gene') :: ['CD19'] @entity3802 :: ('25406(Tax:10116)', 'Gene') :: ['CD44'] @entity2415 :: ('MESH:D004646', 'Disease') :: ['emphysema'] @entity651 :: ('MESH:D055370', 'Disease') :: ['alleviate lung injury', 'Lung injury'] @entity10459 :: ('50683(Tax:10116)', 'Gene') :: ['SPC'] @entity45685 :: ('60350(Tax:10116)', 'Gene') :: ['CD14'] @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive pulmonary disease', 'COPD'] @entity35 :: ('10116', 'Species') :: ['rat', 'Sprague-Dawley rats', 'rats'] @entity18715 :: ('24832(Tax:10116)', 'Gene') :: ['CD90'] @entity18889 :: ('24773(Tax:10116)', 'Gene') :: ['SPA', 'surfactant protein (SP)A'] @entity2383 :: ('MESH:D028361', 'Disease') :: ['alveolar structure']
@entity651 :: (MESH:D055370,Disease) :: ['lung injury']
